REG - Hikma Pharmaceutical - Director/PDMR Shareholding

Hikma PharmaceuticalsAnnouncement

31/08/2023 16:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230831:nRSe0062La&default-theme=true

RNS Number : 0062L  Hikma Pharmaceuticals Plc  31 August 2023

Hikma Pharmaceuticals PLC - LTIP Award

 

LONDON, 31 August 2023: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai:
HIK) (LEI: 549300BNS685UXH4JI75) announces that the Remuneration Committee
made the following conditional award under the Hikma Pharmaceuticals PLC 2023
Long Term Incentive Plan (the "LTIP") to Riad Mishlawi, a Person Discharging
Managerial Responsibility ("PDMR") of the Company. No consideration was paid
for the grant of the award.

The award under the LTIP was made on 31 August 2023 based on a price of £21
per Ordinary Share (being the average mid-market Ordinary Share price for the
for the 5-working day period prior to 31 August 2023, in accordance with the
LTIP rules) (the "LTIP Award"). This LTIP Award reflects Riad Mishlawi's
promotion to Chief Executive Officer of Hikma Pharmaceuticals PLC, effective 1
September 2023 and has been made on a pro-rata basis, taking account of his
LTIP Award granted on 30 May 2023. The vesting of the LTIP Award is subject to
the continued employment of the PDMR, malus and clawback provisions and the
satisfaction of performance conditions set by the Remuneration Committee of
the Company. The LTIP Award will normally vest on the later of the third
anniversary of the date of grant and the determination of the performance
conditions. The LTIP Award is then subject to an additional two-year holding
period.

This notification is made under Article 19(1) of the EU Market Abuse
Regulation 596/2014 as it forms part of domestic law by virtue of the European
Union (Withdrawal) Act 2018 ("MAR"). The information set out below is provided
in accordance with the requirements of Article 19(3) of MAR.

Notification and public disclosure of transactions by persons discharging
managerial responsibilities

 1   Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name                                                                            Riad Mishlawi
 2   Reason for the notification
 a)  Position/status                                                                 PDMR
 b)  Initial notification /Amendment                                                 Initial notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                                            Hikma Pharmaceuticals PLC
 b)  LEI                                                                             549300BNS685UXH4JI75
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument and identification  Description: Ordinary shares of 10 pence each (Shares)
     code

                                                                                     ID Code: GB00B0LCW083
 b)  Nature of the transaction                                                       Grant of award under the LTIP.

 c)  Price(s) and volume(s)                                                          Price(s)                      Volume(s)
     Nil                                                                                                           LTIP Award: 12,623 Shares
 d)  Aggregated information                                                          Price(s): nil

                                                                                     Volume(s): 12,263
 e)  Date of the transaction                                                         31 August 2023
 f)  Place of the transaction                                                        Outside a trading venue

 

Helen Middlemist

Deputy Company Secretary

+44 (0) 20 7399 2760

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBUGDIDBXDGXB